Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer
M Moore, J Maroun, F Robert, R Natale… - Investigational new …, 1993 - Springer
M Moore, J Maroun, F Robert, R Natale, J Neidhart, B Dallaire, R Sisk, J Gyves
Investigational new drugs, 1993•SpringerEighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior
exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered
at a median weekly dose of 1200 mg/m 2 intravenously. The toxicity was moderate, with
thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed
in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no
objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this …
exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered
at a median weekly dose of 1200 mg/m 2 intravenously. The toxicity was moderate, with
thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed
in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no
objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this …
Summary
Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m2 intravenously. The toxicity was moderate, with thirty patients (35%) experiencing grade 3 or 4 toxicity. Objective responses were observed in 1/32 evaluable colorectal and 2/29 evaluable gastric carcinoma patients. There were no objective responses in 17 evaluable pancreatic cancer patients. We conclude that, at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies to warrant further evaluation.
Springer